MGI’s Irofulven Phase III Pancreatic Trial Stopped; Stock Tumbles

MGI Pharma Inc. said it stopped a Phase III trial of irofulven for gemcitabine-refractory pancreatic cancer, thus ending development of the product in that indication, but also said that pivotal Phase III trials of palonosetron achieved the primary endpoint. (BioWorld Today)